CRM vs DHR: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Salesforce, Inc. · Technology
$236.42
+11.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Danaher Corporation · Healthcare
$221.12
+29.6% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+29.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
DHR |
| Current Price |
$236.42 |
$221.12 |
| Fair Value Estimate |
$263.88 |
$286.52 |
| Upside to Fair Value |
+11.6%
|
+29.6%
|
| Market Cap |
$193.6B |
$155.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
14.4x
|
24.8x
|
| Price / Sales |
4.4x
|
6.2x
|
| Price / FCF |
12.8x
|
28.5x
|
| Revenue Growth YoY |
+10.8%
|
+5.5%
|
| Gross Margin |
77.3%
|
58.5%
|
| Operating Margin |
21.4%
|
20.4%
|
| Return on Equity |
20.2%
|
7.7%
|
| Dividend Yield |
0.73% |
0.65% |
| FCF Yield |
7.82%
|
3.51%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4…
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high…
Accumulation Zones
| Metric |
CRM |
DHR |
| Zone Low |
$197.91 |
$214.89 |
| Zone High |
$224.30 |
$243.54 |
| In Buy Zone? |
No
|
Yes
|